Difference between revisions of "Rilzabrutinib (PRN-1008)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trials Registry" to "$1 $1") |
m |
||
| Line 16: | Line 16: | ||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
| − | [[Category:Immune thrombocytopenia medications]] | + | [[Category:Immune thrombocytopenia medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 12:01, 5 July 2024
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
Preliminary data
Immune thrombocytopenia
- PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article PubMed NCT03395210
Also known as
- Code name: PRN-1008